New trick for old drug; Vascepa cost effective for CV reduction - podcast episode cover

New trick for old drug; Vascepa cost effective for CV reduction

Dec 06, 20197 minEp. 82
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

Icosapent ethyl cost effective in REDUCE-IT analysis
Treatment with the fish-derived drug Vascepa for CV event reduction is more effective and less costly than placebo.

*  *  *  

Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019

*  *  *  

DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
The SGLT2 inhibitor had similar efficacy in the elderly and across the spectrum of baseline symptom status.

Colchicine cut post-MI CVD events
Colchicine fulfilled the promise first seem in CANTOS that anti-inflammatory treatment can reduce cardiovascular disease events.

Cardiac arrests peak with pollution in Japan
The incidence of out-of-hospital cardiac arrests in Japan increased on days when counts of particulate matter spiked from the day before.

*  *  *  

For more MDedge Podcasts, go to mdedge.com/podcasts

Email the show: podcasts@mdedge.com

Interact with us on Twitter: @MDedgeTweets

For the best experience, listen in Metacast app for iOS or Android